A Randomised Counter-balanced Intervention Study in Endurance Athletes
Conditions
Brief summary
A randomised counter-balanced intervention study in endurance athletes
Detailed description
To characterise glycaemic, dietary, physiological, and metabolic responses around intense endurance exercise and training in ultra-endurance athletes. Primary objective • Detail the proportion of time spent in glycaemic ranges over a prolonged period of training under the influence of different GI diets in Ultra-endurance athletes. Secondary Objectives * Characterise physiological responses to differing GI diets during a period of extensive endurance exercise through hormonal markers. * Observe the influence of differing GI diets on the impact of endurance performance and short term recovery from endurance exercise, detailing the influence of different GI carbohydrate on the restoration of performance output. * Observe the perception of wellness and gut discomfort using either high or low GI diets supplemented with high or low GI carbohydrates.
Interventions
DIETARY_SUPPLEMENTIsomaltulose
Diet will be supplemented with a beverage containing Isomaltulose as a carbohydrate source.
DIETARY_SUPPLEMENTMaltodextrin
Diet will be supplemented using a beverage containing Maltodextrin.
Sponsors
Beneo GmbH
Swansea University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)
Intervention model description
randomised counter-balanced
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Informed consent obtained * Male or female aged 18-65 years (both inclusive) * Otherwise healthy (as judged by premedical questionnaire) and participating in regular training (volume in training \>10 h training per week) and participating in endurance events and/or VO2max \> 55 ml.kg-1.min-1.
Exclusion criteria
* Receipt of any investigational medicinal product within 1 month prior to screening in this trial * Haemoglobin \<8.0 mmol/L (male) or \<7.0 mmol/L (female). * Systemic (oral or i.v.) corticosteroids, monoamine oxidase (MAO) inhibitors, non-selective beta-blockers, growth hormone and non-routine vitamins and herbal products. Furthermore, thyroid hormones are not allowed unless the use of these has been stable during the past 3 months. * Suffer from or history of a life-threatening disease (i.e. cancer judged not to be in full remission except basal cell skin cancer or squamous cell skin cancer), or clinically severe diseases that directly influence the study results, as judged by the Investigator. This does not prohibit the participation of patients taking medications that influences their metabolism (e.g. statin) or cardio- respiratory system (e.g. asthma spray) as long as the therapy is stable and is not adapted throughout the run of the trial. Furthermore, it does not exclude patients how have coeliac disease (or similar diseases or allergies), as long as the disease is stable, and patients are able to stay on their specific (e.g.) gluten- free diet. * Known cardiac problems defined as decompensated heart failure (New York Heart Association (NYHA) class III and IV) 10 at any time and/or angina pectoris within the last 12 months and/or acute myocardial infarction at any time * Supine blood pressure at screening (after resting for 5 min in supine position) outside the range of 90-140 mmHg for systolic or 50-90 mmHg for diastolic (excluding white-coat hypertension; therefore, if a repeated measurement on a second screening Visit shows values within the range, the participant can be included in the trial). This exclusion criterion also pertains to participants being on anti-hypertensives. * History of clinically significant abnormal ECG issues, as judged by the Investigator. * Severe retinopathy or maculopathy and/or severe neuropathy, in particular autonomic neuropathy, as judged by the Investigator. * Any chronic disorder or severe disease which, in the opinion of the Investigator might jeopardise participant's safety or compliance with the protocol. * History of allergies and/or intolerances to drugs or foods or a history of severe anaphylactic reaction e.g. fructose intolerance. * Significant history of alcoholism or drug/chemical abuse as per Investigator's judgement or a positive result in the urine drug/alcohol screen at the screening Visit. * Smoker (defined as a participant who is smoking more than 5 cigarettes or the equivalent per day). * Not able or willing to refrain from smoking or use of nicotine substitute products during the monitoring period. * Participant with mental incapacity or language barriers precluding adequate understanding or cooperation or who, in the opinion of their general practitioner or the Investigator, should not participate in the trial. * Participating in any other research trial which may interfere with the current study. * Potentially non-compliant or uncooperative during the trial, as judged by the Investigator. * Any condition that would interfere with trial participation or evaluation of results, as judged by the Investigator. * Any known history of diabetes mellitus, or the use of any anti- hyperglycaemic drug or insulin to treat diabetes and related conditions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Interstitial Glucose Percentage Coefficient of Variation. | 24 months | A metric which is related to the daily variation of Interstitial Glucose concentration relative to mean concentration. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| % Time Spent in Range | 24 Months | A characterisation of Interstitial Glucose Concentration in defined ranges.Hyperglycaemia (+7 mmol.L-1), Euglycaemia (4.0-7 mmol.L-1), Hypoglycaemia (\<3.9 mmol.L-1). |
| Performance changes | 24 Months | Physical performance as measured by time to task failure following re-feed protocol of either high or low glycaemic carbohydrates |
| Cardio vascular indicators during exercise | 24 Months | Observing potential changes in the following during repeated exercise trial. Heart rate Vo2 Fuel Oxidization Carbohydrate:Fat oxidization |
| Mean blood and interstitial glucose concentration. | 24 Months | A measure of mean concentration of glucose in both blood and interstitial fluid. |
| Gut distress | 24 Months | Record of potential gut distress via Gastrointestinal Symptom Rating Scale (GSRS). |
| 3. Comparison of lifestyle and wellness when on either high or low Glycaemic diet. | 24 months | Observing impact or changes on daily background activity and sleep. |
| Metabolic and hormonal change in response to re-feed of high or low glycaemic carbohydrate. | 24 Months | Observing any potential adaptation or impact on metabolic or hormones. Assessed through the following Insulin response Intestinal fatty-acid binding protein (iFABP) Triglycerides Glycerol Free Fatty Acids Liver stress enzymes (Alkaline Phosphatase, Aspartate aminotransferase, Alanine transaminase, Gamma-glutamyl transferase & total bilirubin) Cardiac and Muscle enzymes (Heart-type fatty acid binding protein, Cardiac troponin, Creatine kinase & Myoglobin) Ketones |
Countries
United Kingdom
Outcome results
None listed